Treatment Approaches for Women with Positive Cervical Screening Results in Low-and Middle-income Countries
Overview
Affiliations
The primary goal of cervical screening is to identify women with cervical precancers who need treatment to prevent invasive cervical cancer. Cervical cancer screening programs in high-resource settings rely on a multi-step process to reassure the majority of women of low cancer risk and treat the small number of women at high risk of precancer and cancer. The requirement of major resource investment for training and capacity building of multi-step cervical cancer screening programs prevents their introduction in low- and middle-income countries (LMICs). Screen-and-treat programs have been evaluated and introduced in some countries that use mainly ablative treatment as primary treatment options. Ablative treatment with cryotherapy and thermal ablation has a favorable tradeoff of benefits and harms and can be introduced more widely than excisional treatment in LMICs. While most women below 40 are eligible for ablative procedures, fewer than 50% are eligible by age 50 and ablative treatment is not appropriate over age 50. Excisional treatment is required for women ineligible for ablative treatment. Since screening programs in LMICs necessarily detect invasive cancers, cancer treatment and palliative care needs to be considered as well.
Sha Y, Zhang Q, Zhai X, Hou M, Lu J, Meng W iScience. 2024; 27(12):111313.
PMID: 39634563 PMC: 11615576. DOI: 10.1016/j.isci.2024.111313.
Effah K, Tekpor E, Wormenor C, Bosoka S, Afetor M, Dugbazah A BMC Womens Health. 2024; 24(1):428.
PMID: 39060995 PMC: 11282615. DOI: 10.1186/s12905-024-03263-0.
Jain M, Yadav D, Jarouliya U, Chavda V, Yadav A, Chaurasia B Pathogens. 2023; 12(12).
PMID: 38133265 PMC: 10745624. DOI: 10.3390/pathogens12121380.
Sudhakar K, Saravanan D, Hariharan G, Sanaj M, Kumar S, Shaik M Open Life Sci. 2023; 18(1):20220770.
PMID: 38045489 PMC: 10693012. DOI: 10.1515/biol-2022-0770.
Sebitloane H, Forestier M, Ginindza T, Dhlomo W, Moodley-Govender E, Darragh T Cancer Epidemiol Biomarkers Prev. 2023; 33(6):779-787.
PMID: 37955560 PMC: 11145165. DOI: 10.1158/1055-9965.EPI-23-0752.